70 results
8-K
EX-99.1
CCCC
C4 Therapeutics Inc
8 May 24
C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
7:07am
party
Interest and other income, net
Total other income (expense), net
Loss before income taxes
Income tax expense
Net loss per share - basic and diluted
Weighted-average number of shares - basic and diluted
ARS
2024 FY
CCCC
C4 Therapeutics Inc
30 Apr 24
Annual report to shareholders
8:52am
generic products. Our ability to use our net operating loss carryforwards and research and development tax credit carryforwards may be limited … , portions of which expire at various dates through 2043. Under current law, federal net operating losses generated in tax years beginning after 2017
8-K
EX-99.1
f5k7k
22 Feb 24
C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
7:15am
8-K
EX-99.1
013ybsc5
1 Nov 23
C4 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
7:18am
8-K
EX-10.2
jpduk1j
30 May 23
Entry into a Material Definitive Agreement
7:30am
8-K
EX-10.1
e2jq3d3a3kx13ww7ot
30 May 23
Entry into a Material Definitive Agreement
7:30am
ARS
ozakdhu 5upa
28 Apr 23
Annual report to shareholders
7:03am
PRE 14A
e662etbv1zsgbvpx9z
18 Apr 23
Preliminary proxy
7:59am